Biogen first-quarter sales rise 6.7 percent
April 21, 2016 at 07:27 AM EDT
April 21 (Reuters) - Biogen Inc's quarterly sales rose 6.7 percent, helped by growing demand for its key oral multiple sclerosis (MS) drug, Tecfidera.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.